Olema Oncology

Olema Oncology is a biopharmaceutical company dedicated to developing innovative targeted therapies for women's cancers. The company’s lead program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) currently in development for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.